坦索罗辛联合索利那新治疗前列腺增生所致下尿路症状的临床研究  

Tamsulosin combined with solifenacin in the treatment of lower urinary tract symptoms induced by benign prostate hyperplasia

作　　者：宋彦[1] 金玮[1] 华声瑜[2] 费翔[1] 

机构地区：[1]中国医科大学附属盛京医院泌尿外科,沈阳110004 [2]天津中医药大学中医院研究院天津市省部共建重点实验室,天津300193

出　　处：《实用药物与临床》2016年第2期200-203,共4页Practical Pharmacy and Clinical Remedies

基　　金：沈阳市科学技术计划项目(F11-262-9-12)

摘　　要：目的探讨联合应用高选择性α受体阻滞剂(坦索罗辛)和M受体阻滞剂(索利那新)治疗前列腺增生(BPH)致下尿路症状(LUTS)的临床疗效及安全性。方法回顾性分析2013年4月至2015年6月我院127例前列腺增生致下尿路症状患者的临床资料。入选病例按治疗方式不同分为2组,坦索罗辛组76例,单独应用坦索罗辛0.2mg/d治疗2周;联合治疗组51例,应用坦索罗辛0.2mg/d+索利那新5mg/d,治疗2周。记录、比较治疗前后两组患者的国际前列腺症状评分(IPSS)、最大尿流率(Qmax)、OAB症状评分(OABSS),同时观察药物不良反应。结果治疗前、后,坦索罗辛组IPSS为14.5±4.7、11.5±3.6(P>0.05),Qmax为12.5±3.4、17.3±6.4(P<0.05),OABSS为8.4±1.8、7.3±1.6(P>0.05),PSA为(4.1±2.1)、(4.1±3.4)ng/m L(P>0.05),仅Qmax治疗前后比较差异有统计学意义;联合治疗组IPSS为15.1±4.1、7.7±3.9(P<0.05),Qmax为11.8±4.5、17.4±5.5(P<0.05),OABSS为8.3±1.5、5.4±2.1(P<0.05),PSA为(4.1±3.6)、(4.2±4.1)ng/m L(P>0.05),除PSA外,其余各项差异均有统计学意义。治疗后,联合治疗组的IPSS、OABSS低于坦索罗辛组(P<0.05)。全部患者均无严重并发症出现,坦索罗辛组、联合治疗组的药物不良反应发生率比较差异无统计学意义(27.6%vs.30.0%,P>0.05)。结论联合应用坦索罗辛、索利那新能明显缓解BPH导致男性下尿路症状,改善患者的生活质量,未见严重不良反应。Objective To evaluate the safety and efficacy of tamsulosin and solifenacin in treating lower urinary tract symptom（LUTS） induced by benign prostate hyperplasia（BPH）.Methods A total of 127 patients with LUTS induced by BPH from April 2013 to June 2015 were divided into 2 groups.Patients in tamsulosin group（n =76）were treated by tamsulosin 0.2 mg/d,patients in combination group（n=51） were given tamsulosin 0.2 mg/d and solifenacin 5 mg/d.After 2 weeks of treatment,the IPSS,Qmax and OABSS were compared between the two groups,and the adverse reactions were observed.Results There was significant difference in Qmax（12.5 ± 3.4 vs.17.3 ±6.4,P 〈 0.05） of tamsulosin group before and after treatment,while no obvious difference was found in IPSS（14.5 ±4.7 vs.11.5±3.6,P 〈0.05）,OABSS（8.4 ± 1.8 vs.7.3 ± 1.6,P〉0.05） and PSA（ng/mL）（4.1 ±2.1 vs.4.1 ±3.4,P 〉0.05）.There was significant difference in IPSS（15.± 14.1 vs.7.7±3.9,P 〈0.05）,Qmax（11.8±4.5 vs.17.4 ±5.5,P 〈0.05） and OABSS（8.3 ± 1.5 vs.5.4 ±2.1,P 〈 0.05）,while no obvious difference was found in PSA（ng/mL）（4.1 ±3.6 vs.4.2 ±4.1,P 〉0.05）.The combination therapy exhibited an obvious superiority over tamsulosin alone in improving IPSS（7.7 ±3.9 vs.11.5 ± 3.6,P 〈 0.05） and OABSS（5.4 ± 2.1 vs,7.3 ± 1.6,P 〈0.05）.No significant difference was observed in the incidence of adverse reaction between tamsulosin group and combination group（27.6%vs.30.0%,P 〉 0.05）.Conclusion Combination therapy of tamsolusin and solifenacin can greatly improve the LUTS induced by BPH without severe adverse reaction.

关 键 词：坦索罗辛 索利那新 前列腺增生 下尿路症状 

分 类 号：R697.3[医药卫生—泌尿科学]